-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A paper published by "Nature" BNT162b2-elicited neutralization of B.
1.
617 and other SARS-CoV-2 variants reported that the serum vaccinated with Pfizer-BioNTech's new coronavirus vaccine neutralized the new virus
.
The sera of people who received two doses of the vaccine neutralized the B.
1.
617.
2 (also known as delta) variant (first discovered in India) and some other variants, including B.
1.
525 (first discovered in Nigeria)
.
With the emergence of new variants of the new coronavirus, it is urgent to evaluate the immune effects of existing vaccines to produce antibodies and neutralize these variants
.
The World Health Organization has designated B.
1.
617.
2 as the new coronavirus mutant strain that needs attention, and B.
1.
525 as the mutant strain that needs attention
.
Peiyong Shi of the University of Texas Medical Branch at Galveston and his colleagues used 20 serum samples from fifteen people who had received two doses of Pfizer-BioNTech vaccine to test the neutralization of the serum against the recombinant new coronavirus.
Active, these viruses express the spike protein of B.
1.
617.
2, B.
1.
617.
1, B.
1.
618 (first discovered in India) and B.
1.
525 mutant strain
.
Compared with the virus strains isolated in January 2020, the serum has lower activity against the mutant strains—especially the B.
617.
1 mutant strain—but studies have observed that the serum has a robust neutralizing effect on all tested mutant strains
.
The authors concluded that this finding suggests that the vaccine may provide adequate protection against these new variants
.
The author compared these results with the vaccine’s test on the B.
1.
351 variant (or beta variant, found in South Africa), and found that there was a decrease in neutralizing activity similar to that of B.
1.
617.
1, but the vaccine still showed resistance.
B.
1.
351 75% effectiveness for infections and 100% effectiveness for serious or fatal diseases
.
The authors concluded that the report on the effectiveness of the vaccine against variant strains shows the importance of the vaccination schedule, which may reduce the emergence of new variant strains
.
Use BNT162b2 immune serum to neutralize the new coronavirus mutant strain
.
Source: Liu et al.
©NatureNature | doi: 10.
1038/s41586-021-03693-y
1.
617 and other SARS-CoV-2 variants reported that the serum vaccinated with Pfizer-BioNTech's new coronavirus vaccine neutralized the new virus
.
The sera of people who received two doses of the vaccine neutralized the B.
1.
617.
2 (also known as delta) variant (first discovered in India) and some other variants, including B.
1.
525 (first discovered in Nigeria)
.
With the emergence of new variants of the new coronavirus, it is urgent to evaluate the immune effects of existing vaccines to produce antibodies and neutralize these variants
.
The World Health Organization has designated B.
1.
617.
2 as the new coronavirus mutant strain that needs attention, and B.
1.
525 as the mutant strain that needs attention
.
Peiyong Shi of the University of Texas Medical Branch at Galveston and his colleagues used 20 serum samples from fifteen people who had received two doses of Pfizer-BioNTech vaccine to test the neutralization of the serum against the recombinant new coronavirus.
Active, these viruses express the spike protein of B.
1.
617.
2, B.
1.
617.
1, B.
1.
618 (first discovered in India) and B.
1.
525 mutant strain
.
Compared with the virus strains isolated in January 2020, the serum has lower activity against the mutant strains—especially the B.
617.
1 mutant strain—but studies have observed that the serum has a robust neutralizing effect on all tested mutant strains
.
The authors concluded that this finding suggests that the vaccine may provide adequate protection against these new variants
.
The author compared these results with the vaccine’s test on the B.
1.
351 variant (or beta variant, found in South Africa), and found that there was a decrease in neutralizing activity similar to that of B.
1.
617.
1, but the vaccine still showed resistance.
B.
1.
351 75% effectiveness for infections and 100% effectiveness for serious or fatal diseases
.
The authors concluded that the report on the effectiveness of the vaccine against variant strains shows the importance of the vaccination schedule, which may reduce the emergence of new variant strains
.
Use BNT162b2 immune serum to neutralize the new coronavirus mutant strain
.
Source: Liu et al.
©NatureNature | doi: 10.
1038/s41586-021-03693-y
